Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BLTE, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA | Options-implied move |
|---|---|---|---|---|---|
| 2027-02-12 | tinlarebant | Stargardt disease type 1 (STGD1) | NDA | 71% | ±35% by Mar 19 |
Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Tinlarebant | Geographic Atrophy | Phase 3 · NCT05949593 | Active not recruiting |
| BPN-14967 | Healthy Volunteers | Phase 1 · NCT04005807 | Completed |
| LBS-008 | Healthy Volunteer | Phase 1 · NCT03735810 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BLTE reported $492.4M in cash and short-term investments (as of Dec 31, 2025) and used about $9.2M/quarter in operations, an estimated runway of 159.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 32 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BLTE files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | Institution (13G, 5%+) | 3,027,704 | 7.70% | 2025-12-31 |
| Hao-Yuan Chuang Chief Financial Officer, Director · +289,736 options |
Insider | 210,264 | 0.53% | 2026-10-29 |
| Yu-Hsin Lin Chief Executive Officer, Director · +413,908 options |
Insider | 187,949 | 0.48% | 2026-10-29 |
| Wan-Shan Chen Director · +13,796 options |
Insider | 37,259 | 0.09% | 2026-09-24 |
| Hendrik Peter Scholl Chief Medical Officer · +10,000 options |
Insider | 12,500 | 0.03% | 2026-11-12 |
| Xiao-Hui Chen Director |
Insider | 400 | 0.00% | 2026-03-18 |
Share count 39,339,960 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BLTE and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →